[go: up one dir, main page]

WO2009032694A1 - Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse - Google Patents

Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse Download PDF

Info

Publication number
WO2009032694A1
WO2009032694A1 PCT/US2008/074472 US2008074472W WO2009032694A1 WO 2009032694 A1 WO2009032694 A1 WO 2009032694A1 US 2008074472 W US2008074472 W US 2008074472W WO 2009032694 A1 WO2009032694 A1 WO 2009032694A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
isopropylsulfonyl
ylamino
chloro
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/074472
Other languages
English (en)
Inventor
Nathanael Gray
Taebo Sim
Hwan Guen Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Priority to AU2008296479A priority Critical patent/AU2008296479A1/en
Publication of WO2009032694A1 publication Critical patent/WO2009032694A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • Cancer is a disease resulting from an abnormal growth of tissue. Certain cancers have the potential to invade into local tissues and also metastasize to distant organs. This disease can develop in a wide variety of different organs, tissues and cell types. Therefore, the term "cancer” refers to a collection of over a thousand different diseases. Despite advancements in the art, there remains a need for cancer treatments and anti-cancer compounds.
  • the present invention is based on the discovery that certain pyrimidine derivatives possess valuable, pharmacologically useful properties.
  • the pyrimidine derivatives used according to the present invention exhibit specific inhibitory activities that are of pharmacological interest. They are effective especially as protein tyrosine kinase inhibitors; they exhibit, for example, powerful inhibition of the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) and the fusion protein of NPM-ALK .
  • This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and the anaplastic lymphoma kinase (ALK), rendering the protein tyrosine kinase activity of ALK ligand-independent.
  • NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas.
  • ACL anaplastic large-cell lymphoma
  • NHL non-Hodgkin's lymphomas
  • IMT myofibroblastic tumors
  • NPM-ALK other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK).
  • ALK has been shown to become translocated to the echinoderm microtubule-associate protein-like 4 (EML4) in a subset of patients afflicted with Non small cell lung cancer (NSCLC).
  • EML4-ALK fusion tyrosine kinase generated transformed foci in culture and subcutaneous tumors in mice. Therefore EML4-ALK, which is inhibited by the compounds described in this application, maybe a relevant target for NSCLC patients or other patients with this or related ALK- containing fusion proteins (Nature. 2007 Aug 2;448(7153):561-6)
  • the pyrimidine derivatives are useful for the inhibition of all such ALK-containing gene fusions.
  • the pyrimidine derivatives used according to the present invention also exhibit inhibition of the mitotic assembly checkpoint kinase MPSl (also known as TTK).
  • MPSl also known as TTK
  • the enzymatic activity of this kinase is required for cells to undergo a mitotic checkpoint arrest in response to agents that disrupt mitosis such as compounds that interfere with tubulin polymerization/depolymerization.
  • Normal cells have multiple redundant mechanisms for arresting in mitosis whereas cancer cells have a heightened dependence on TTK activity.
  • agents that can inhibit TTK kinase maybe able to preferentially kill tumor cells.
  • One embodiment of this invention encompasses a compound having the formula (I):
  • Z is N or CH
  • A is aryl or heteroaryl optionally substituted with one or more R groups
  • B is phenyl when Z is N; or B is phenyl, pyrazolyl or thiazolyl when Z is CH; wherein
  • Y is -SO 2 -, -SO 2 NH-, -NH-SO 2 -, -NH-C(O)-, -C(O)-NH-, -O-, Or-NR 2 -;
  • each occurrence of X is independently NH, O or S;
  • R 1 is H, C 1- C 6 alkyl, 1IaIo-(C 1 -C 6 alkyl), C r C 6 cycloalkyl, halo-(C 1 -C 6 cycloalkyl), heterocyclyl, aryl, arylC 1 . 6 alkyl, heteroaryl or heteroarylC 1-6 alkyl;
  • R 2 is H, C 1- C 6 alkyl, halo-(d-C 6 alkyl), C 1- C 6 cycloalkyl, halo-(d-C 6 cycloalkyl), heterocyclyl, heterocyclylC 1- ⁇ alkyl, aryl, heteroaryl or heteroarylC 1-6 alkyl;
  • R 3 is R 4 , -CO-R 5 —o ' 1— N O
  • R a is hydrogen and R b is halogen, or R a and R b , taken together with the atoms to which they are bound form i) a pyrazolo ring fused to the pyrimidine ring when Z is N or ii) a pyrrolo ring fused to the the pyrimidine ring when Z is CH, said pyrazolo or pyrrolo ring optionally bearing one or two R 4 groups;
  • Each occurrence of R 4 is independently halogen, C 1 -C 6 alkyl, halo-(C 1 -C 6 alkyl), C 1 - C 6 cycloalkyl, halo-(C 1 -C 6 cycloalkyl), heterocyclyl, heterocyclylC 1-6 alkyl, aryl, arylC 1 ⁇ alkyl, heteroaryl or hydroxyl, nitro, azido, cyano, acyloxy, carboxy, ester, carbamoyl, carboxamide, ureido, amidino, guanidine, sulfonyl, sulphonylamino, aminosulphonyl;
  • Each occurrence of R 5 is independently is C 1 -C 6 alkoxy, ⁇ — / , hydroxy, , dialkylamino, or -N-R 7 ; i / ⁇ i / ⁇ 7
  • Each occurrence of R 6 is independently is hydroxy, ⁇ — ' , ⁇ — / , or -
  • R 7 is independently is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxyl, or C 1 -C 6 hydroxyalkyl;
  • -X-R 2 is bound in the meta or para position on the phenyl group and R and R , if present on B, are not bound to the meta or para position and are not -COR 5 , C 1 -C 6 alkyl, Mo-(C 1 -C 6 alkyl), C 1 -C 6 cycloalkyl, halo-(C 1 -C 6 cycloalkyl), heterocyclyl, heteroaryl or heteroarylC 1 . 6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, cyano, acyloxy, carboxy, ester, carbamoyl, carboxamide or amidino ;
  • R 3 is bound to the meta or para position
  • R 3 and R 4 are each bound to the meta or para position and are independently nitro, azido, ureido, guanidine, sulphonylamino ;
  • (a) -X-R 2 is not isopropoxy bound to the othro postion and R 3 or R 4 , if present on B, is methyl, ethyl, methoxy, ethoxy, chloro or bromo any of which is bound to the ortho postion
  • R 3 and R 4 are each bound to the meta or para position and are independently is C 1-6 alkoxy, C 1-6 alkylthio, hydroxyl, nitro, azido, cyano, acyloxy, carboxy, ester, carbamoyl, carboxamide, ureido, amidino, guanidine, sulfonyl, sulphonylamino, aminosulphonyl; -CO-R 5 , or phenyl substituted with aminosulphonyl, amino, alkynyl or carboxamide.
  • the invention encompasses a compound having the formula (IA):
  • the invention encompasses a compound having the formula (II):
  • the invention encompasses a compound having the formula (III):
  • the invention encompasses a compound of formula I, IA, II or III, wherein X is O. In still other embodiments, the invention encompasses a compound of formula I, IA, II or III, wherein R 2 is methyl, ethyl, propyl, isopropyl, cyclopropyl or cyclobutyl.
  • the invention encompasses a compound of formula I, IA, II or III, wherein R 2 is methyl.
  • the invention encompasses a compound of formula I, IA, II or III, wherein Y is SO 2 .
  • the invention encompasses a compound of formula I, IA, II or III, wherein R 1 is methyl, ethyl, propyl, isopropyl, cyclopropyl or cyclobutyl.
  • the invention encompasses a compound of formula I, IA, II or III, wherein R 1 is isopropyl. In yet another embodiment, the invention encompasses a compound of formula I, IA,
  • Another aspect of the invention encompasses a compound having the IUPAC name:
  • Another aspect of the invention encompasses a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to Formula I, IA, II or III or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof and a pharmaceutically acceptable diluent or carrier.
  • the pharmaceutical composition encompasses a composition wherein the compound is present in a therapeutically effective amount.
  • the pharmaceutical composition the invention further encompasses at least one further active compound, hi one embodiment, the further active compound is an anti-hyperproliferative agent.
  • Another aspect of the invention encompasses a packaged pharmaceutical composition comprising a container, the pharmaceutical composition of the invention and instructions for using the pharmaceutical composition to treat a disease or condition in a mammal.
  • Yet another aspect of the invention encompasses a method of inhibiting kinase activity in a cell comprising contacting a cell with one or more compounds of the invention.
  • the kinase activity inhibited is Anaplastic Lymphoma Kinase activity.
  • the kinase activity inhibited is hepatocyte growth factor receptor tyrosine kinase (c-Met) activity.
  • the kinase activity inhibited is monopolar spindle (Mpsl) kinase activity.
  • Still another aspect of the invention encompasses a method of treating a hyperproliferative disorder in a mammal comprising administering to a mammal in need thereof, a therapeutically effective amount of one or more compounds of the invention.
  • the hyperproliferative disorder is cancer, including but not limited to, cancer of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid or a distant metastasis of a solid tumor, a lymphoma, sarcoma, melanoma or leukemia.
  • Still yet another aspect of the invention encompasses a method of treating an angiogenesis disorder in a mammal comprising administering to a mammal in need thereof, a therapeutically effective amount of one or more compounds of the invention.
  • terms such as “comprises”, “comprised”, “comprising” and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of and “consists essentially of” have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
  • halogen refers to radicals of fluorine, chlorine, bromine and iodine.
  • alkyl refers to a straight or branched hydrocarbon chain radical, containing solely carbon and hydrogen atoms, having in the range from one up to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, such as illustratively, methyl, ethyl, n-propyl 1-methylethyl (iso-propyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (tert-butyl).
  • cycloalkyl denotes a non-aromatic mono or multicyclic ring system having in the range of 3 up to 14 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • multicyclic cycloalkyl groups include decahydronapththyl.
  • bridged cycloalkyl groups or sprirobicycloalkyl groups include adamantyl norbornyl, and sprio[4.4]nonyl groups.
  • alkoxy denotes an alkyl group as defined herein attached via an oxygen linkage to the rest of the molecule. Representative examples of those groups are methoxy, ethoxy, iso-propoxy, n-butoxy, and tert-butoxy.
  • cycloalkoxy denotes a cycloalkyl group as defined herein attached via an oxygen linkage to the rest of the molecule. Representative examples of those groups are cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, and cycloheptoxy.
  • aryl refers to aromatic radicals having in the range of 6 up to 14 carbon atoms such as phenyl, naphthyl, indanyl, and biphenyl.
  • heteroaryl refers to a stable 5- to 13-membered aromatic heterocycle having in the range of from 1 up to 4 heteroatoms from the group consisting of nitrogen, phosphorus, oxygen and sulfur, which ring or ring system can be linked via a carbon atom or a nitrogen atom, if such an atom is present.
  • the heteroaryl ring radical may be a monocyclic, bicyclic or tricyclic ring system.
  • heteroaryl radicals examples include: pyridyl, pyridyl N-oxide, pyrimidyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl or isoxazolyl, indolicenyl, indolyl, benzo[b]thienyl, benzo[b]furyl, benzothiazolyl, benzothiadiazolyl, indazolyl, quinolyl, isoquinolyl, isoquinolyl, naphthyridinyl, quinazolinyl, oxadiazolyl, benzoxazolyl, tetrazoyl, triazolyl, thiadiazolyl, and benzimidazolyl.
  • heterocycloalkyl refers to a stable 3 to 13 membered saturated or partially unsaturated heterocycle having in the range from 1 up to 4 heteroatoms from the group consisting of nitrogen, phosphorus, oxygen and sulfur, which ring or ring system can be linked via a carbon atom or a nitrogen atom, if such an atom is present.
  • the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems.
  • heterocyclyl radicals examples include: tetrahydropyranyl, aziridyl, azepanyl, tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, piperidinyl, 1,2 dihydropyridinyl, 1,4 dihydropyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepinyl, oxazolinyl, thiazolinyl and 1,4 diazepinyl.
  • alkylamino refers to an alkyl group as defined herein attached via amino linkage to the rest of the molecule.
  • alkylamino further includes dialkyl amino moieties in which two alkyl groups as define herein are attached via amino linkage to the rest of the molecule. Representative examples of those groups are methylamino and dimethylamino. Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like.
  • the compounds of this invention may contain one or more asymmetric centers, depending upon the location and nature of the various substituents desired.
  • Asymmetric carbon atoms may be present in the (R) or (S) configuration, resulting in racemic mixtures in the case of a single asymmetric center, and diastereomeric mixtures in the case of multiple asymmetric centers.
  • asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
  • Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the present invention.
  • Preferred compounds are those which produce the more desirable biological activity.
  • Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention.
  • the purification and the separation of such materials can be accomplished by standard techniques known in the art.
  • the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
  • appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid.
  • Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallization.
  • the optically active bases or acids are then liberated from the separated diastereomeric salts.
  • a different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivitization, optimally chosen to maximize the separation of the enantiomers.
  • Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable.
  • Enzymatic separations, with or without derivitization are also useful.
  • the optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.
  • the present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts, co-precipitates, metabolites, hydrates, solvates and prodrugs of all the compounds of examples.
  • pharmaceutically acceptable salt refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1-19.
  • Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
  • Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, magnesium, ammonium, and chorine salts.
  • acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
  • alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
  • Representative salts of the compounds of this invention include the conventional nontoxic salts and the quaternary ammonium salts which are formed, for example, from inorganic or organic acids or bases by means well known in the art.
  • acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesulfonate, 2-
  • Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine. Additionally, basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides
  • a solvate for the purpose of this invention is a complex of a solvent and a compound of the invention in the solid state.
  • Exemplary solvates would include, but are not limited to, complexes of a compound of the invention with ethanol or methanol. Hydrates are a specific form of solvate wherein the solvent is water.
  • the present invention relates to a method for using the compounds of the present invention and compositions thereof, to treat mammalian hyper-proliferative disorders.
  • Compounds can be utilized to inhibit, block, reduce, decrease, etc., cell proliferation and/or cell division, and/or produce apoptosis.
  • This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; etc. which is effective to treat the disorder.
  • Hyper-proliferative disorders include but are not limited, e.g., psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.
  • BPH benign prostate hyperplasia
  • solid tumors such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.
  • Those disorders also include lymphomas, sarcomas, and leukemias.
  • breast cancer examples include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
  • cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
  • brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.
  • Tumors of the male reproductive organs include, but are not limited to prostate and testicular cancer.
  • Tumors of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
  • Tumors of the digestive tract include, but are not limited to anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.
  • Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
  • Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.
  • liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
  • Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
  • Head-and-neck cancers include, but are not limited to laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell.
  • Lymphomas include, but are not limited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
  • Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
  • Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
  • treating or “treatment” as stated throughout this document is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder, such as a carcinoma.
  • metastasis in the original organ or tissue and/or in any other location are implied alternatively or in addition, whatever the location of the tumor and/or metastasis.
  • Compounds of the invention are selectively toxic or more toxic to rapidly propiferating cells than to normal cells, particularly in human cancer cells, e.g., cancerous tumors, the compound has significant antiproliferative effects and promotes differentiation, e.g., cell cycle arrest and apoptosis.
  • the present invention also provides methods for the treatment of disorders associated with aberrant expression of Anaplastic Lymphoma Kinase, Hepatocyte growth factor receptor tyrosine kinase (c-Met), and/or Nucleophosmin-ALK.
  • Anaplastic Lymphoma Kinase Hepatocyte growth factor receptor tyrosine kinase (c-Met)
  • c-Met Hepatocyte growth factor receptor tyrosine kinase
  • Nucleophosmin-ALK Nucleophosmin-ALK
  • the compounds described in this application are ATP-competitive kinase inhibitors. As such they competitively block ATP from binding to the kinase active site and thereby prevent phosphorylation of downstream substrates. This effectively blocks signal transduction from the targeted kinases.
  • Compounds in this application have the potential to interact with any kinase in the human kinome and have been tested for their ability to bind to a panel of 320 distinct protein kinases.
  • This panel includes the following kinases: AAKl, ABLl, ABL1(E255K), ABL1(H396P), ABL1(M351T), ABL1(Q252H), ABL1(T315I), ABL1(Y253F), ABL2, ACVRl, ACVRlB, ACVR2A, ACVR2B, ACVRLl,
  • the compounds of the invention demonstrate inhibitory activity against: ADCK3, ADCK4, ALK, CLKl, CLK4, EGFR, EGFR(E746-A750del), EGFR(L747- E749del, A750P), EGFR(L747-S752del, P753S), EGFR(L747-T751del,Sins), EGFR(L858R), EGFR(L861Q), EGFR(S752-I759del), ERBB4, FER, FES, GAK, IGFlR, INSR, INSRR, LTK, PTK2, PTK2B, ROSl, RPS6KAl(Kin.Dom.2), TNKl, TNK2, TTK.
  • the ALK inhibitory activity and inhibitory activity against ALK-containing gene fusions of the compounds described herein make them useful pharmaceutical agents for the treatment of proliferative diseases.
  • the inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with other
  • a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
  • Proliferative diseases treated according to the present method include tumors of blood and lymphatic system (e.g.
  • Hodgkin's disease Non-Hodgkin's lymphoma, Burkitt's lymphoma, AIDS-related lymphomas, malignant immunoproliferative diseases, multiple myeloma and malignant plasma cell neoplasms, lymphoid leukemia, acute or chronic myeloid leukemia, acute or chronic lymphocytic leukemia, monocytic leukemia, other leukemias of specified cell type, leukemia of unspecified cell type, other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues, for example diffuse large cell lymphoma, T-cell lymphoma or cutaneous T-cell lymphoma).
  • Myeloid cancer includes e.g. acute or chronic myeloid leukaemia.
  • the present invention also provides methods of treating disorders and diseases associated with aberrant expression of the monopolar spindle kinase (Mpsl, also known as TTK)
  • Mpsl monopolar spindle kinase
  • Mpsl Monopolar spindle (Mpsl also known as TTK) kinase is a kinase for mitotic checkpoint and also controls correction of improper chromosome attachments. Both of these processes are important in maintaining chromosomal stability during cell division. Agents that block of Mpsl kinase activity may find application in cancer therapy due to their ability to induce apoptosis of cells that contain an improper number of chromosomes, hi addition, Agents that block of Mpsl kinase activity may further enhance cytotoxicity of other chemotherapeutic agents.
  • the present invention also provides methods of treating disorders and diseases associated with aberrant expression of the neurotrophic growth factor receptor tyrosine kinase A, B and C (Trk A, B, C also known as NTRKl, 2, and 3).
  • the compounds in the present invention exhibit inhibition of the neurotrophic growth factor receptor tyrosine kinase A, B and C (Trk A, B, C also known as NTRKl, 2, and 3).
  • Nrk A, B, C also known as NTRKl, 2, and 3
  • Several lines of evidence have implicated NTRKs in the development and progression of cancer through deregulation of tyrosine kinase activity by mutations, chromosomal rearrangements, upregulation of either the receptor, their ligand (Nerve Growth Factor, Brain Derived Neurotropic Factor, Neurotrophins) or both. Chromosomal translocations involving both NTRKl & 3 have been found in several different types of tumors.
  • TrkB is of central importance in preventing anoikis (detachment-induced apoptosis) which is believed to an important requirement in the metastatic process.
  • the present invention also provides methods of treating disorders and diseases associated with excessive and/or abnormal angiogenesis.
  • Inappropriate and ectopic expression of angiogenesis can be deleterious to an organism.
  • a number of pathological conditions are associated with the growth of extraneous blood vessels. These include, e.g., diabetic retinopathy, ischemic retinal-vein occlusion, and retinopathy of prematurity (Aiello et al. New Engl. J. Med. 1994, 331, 1480; Peer et al. Lab. Invest. 1995, 72, 638), age-related macular degeneration (AMD; see, Lopez et al. Invest. Opththalmol. Vis. Sci.
  • neovascular glaucoma neovascular glaucoma, psoriasis, retrolental fibroplasias, angiofibroma, inflammation, rheumatoid arthritis (RA), restenosis, in-stent restenosis, vascular graft restenosis, etc.
  • RA rheumatoid arthritis
  • restenosis in-stent restenosis
  • vascular graft restenosis etc.
  • the increased blood supply associated with cancerous and neoplastic tissue encourages growth, leading to rapid tumor enlargement and metastasis.
  • the growth of new blood and lymph vessels in a tumor provides an escape route for renegade cells, encouraging metastasis and the consequence spread of the cancer.
  • compounds of the present invention can be utilized to treat and/or prevent any of the aforementioned angiogenesis disorders, e.g., by inhibiting and/or reducing blood vessel formation; by inhibiting, blocking, reducing, decreasing, etc. endothelial cell proliferation or other types involved in angiogenesis, as well as causing cell death or apoptosis of such cell types.
  • the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication.
  • the amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
  • the total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day.
  • the average daily oral dosing will be from about 200 mg/day to about 600 mg/day which corresponds to 2.8-8.6 mg/kg for a person with an average weight of 70 kgs.
  • Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing.
  • "drug holidays" in which a patient is not dosed with a drug for a certain period of time may be beneficial to the overall balance between pharmacological effect and tolerability.
  • a unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day.
  • the average daily dosage for administration by injection including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily.
  • the transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg.
  • the average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
  • the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like.
  • the desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.
  • the compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects.
  • the compounds of this invention can be combined with known anti-hyper-proliferative or other indication agents, and the like, as well as with admixtures and combinations thereof.
  • the additional pharmaceutical agent can be aldesleukin, alendronic acid, alfaferone, alitretinoin, allopurinol, aloprim, aloxi, altretamine, aminoglutethimide, amifostine, amrubicin, amsacrine, anastrozole, anzmet, aranesp, arglabin, arsenic trioxide, aromasin, 5- azacytidine, azathioprine, BCG or tice BCG, bestatin, betamethasone acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulfate, broxuridine , bortezomib, busulfan, calcitonin, campath, capecitabine, carboplatin, casodex, cefesone, celmoleukin, cerubidine, chlorambucil, cisplatin, cladribine, cladribine, clodronic
  • Optional anti-hyper-proliferative agents which can be added to the composition include but are not limited to compounds listed on the cancer chemotherapy drug regimens in the 11 th Edition of the Merck Index, (1996), which is hereby incorporated by reference, such as asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, prednisone
  • anti-hyper-proliferative agents suitable for use with the composition of the invention include but are not limited to those compounds acknowledged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition), editor Molinoff et al., publ.
  • Preferred modes of administration include oral administration and parenteral administration.
  • compositions comprising them that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups).
  • dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa. (1990).
  • Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques.
  • Excipients can take a wide variety of forms depending on the form of preparation desired for administration.
  • excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
  • excipients suitable for use in solid oral dosage forms include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.
  • tablets and capsules represent very advantageous oral dosage unit forms, in which case solid excipients are employed.
  • tablets can be coated by standard aqueous or nonaqueous techniques.
  • dosage forms can be prepared by any of the methods of pharmacy.
  • pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
  • a tablet can be prepared by compression or molding.
  • Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with an excipient.
  • Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.
  • Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
  • natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl
  • fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
  • the binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.
  • Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH-101, AVICEL-PH- 103 AVICEL RC-581, AVICEL-PH- 105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, Pa.), and mixtures thereof.
  • An specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC-581.
  • Suitable anhydrous or low moisture excipients or additives include AVICEL-PH- 103.TM and Starch 1500 LM.
  • Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment.
  • Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions.
  • a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention.
  • the amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, specifically from about 1 to about 5 weight percent of disintegrant.
  • Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
  • Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof.
  • Additional lubricants include, for example, a syloid silica gel (AEROSIL 200, manufactured by W.
  • lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
  • Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection and constant infusion), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products (including, but not limited to lyophilized powders, pellets, and tablets) ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
  • Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection,
  • Ringer's Injection Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol
  • non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • Transdermal, topical, and mucosal dosage forms of the invention include, but are not limited to, ophthalmic solutions, sprays, aerosols, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton Pa. (1980 & 1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels. Further, transdermal dosage forms include "reservoir type" or "matrix type” patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.
  • Suitable excipients e.g., carriers and diluents
  • other materials that can be used to provide transdermal, topical, and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
  • excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane- 1, 3 -diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form lotions, tinctures, creams, emulsions, gels or ointments, which are non-toxic and pharmaceutically acceptable.
  • Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton Pa. (1980 & 1990).
  • penetration enhancers can be used to assist in delivering the active ingredients to the tissue.
  • Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).
  • the pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied may also be adjusted to improve delivery of one or more active ingredients.
  • the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
  • Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
  • stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
  • Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
  • Kits This invention encompasses kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.
  • kits of the invention comprises one or more unit dosage forms of a compound of the invention or one or more compositions comprising a compound of the invention, or physiologically acceptable salts thereof, and instructions for use.
  • Kits of the invention can further comprise devices that are used to administer a compound of the invention to a patient. Examples of such devices include, but are not limited to, intravenous cannulation devices, syringes, drip bags, patches, topical gels, pumps, tubing, containers that provide protection from photodegredation, and inhalers.
  • Kits of the invention can further comprise pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients.
  • the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration.
  • Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
  • water-miscible vehicles such as, but not limited to, ethyl alcohol
  • the compounds of Formula I, particularly Formula IA can be prepared through the preparation shown in the Reaction Scheme 1 below.
  • the compounds of Formula I, particularly Formula IA can be prepared through the preparation shown in the Reaction Scheme 2 below.
  • reaction mixture was poured into ice water and the resulting white solid was filtered and dried, yielding (560 mg) mixture of two isomers 2,5- dichloro-N 4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-4,6-diamine and 5,6-dichloro-N 4 -(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine.
  • a sealed tube was charged with the isomers of 2,5-dichloro-N 4 -(2- (isopropylsulfonyl)phenyl)pyrimidine-4,6-diamine and 5,6-dichloro-N 4 -(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (100 mg, 0.28 mmol), l-(4-amino-3- methoxyphenyl)piperidin-4-ol (123 mg, 0.56 mmol), 4NHC1 dioxane (0.14 mL) and 2- butanol (1.0 mL). The tube was sealed and the reaction mixture was stirred at 120 °C for 24 hours.
  • reaction mixture was then partitioned between ethyl acetate and water.
  • the organic layer was separated and the aqueous layer was neutralized with satd. NaHCO 3 solution and extracted with ethyl acetate.
  • the combined organic extracts were washed with brine, dried over MgSO 4 , filtered and concentrated.
  • the residue was dissolved in DMSO (3mL).
  • the resulting solution was subjected to purification by reverse-phase HPLC to yield the title compound as a TFA salt.
  • the product containing fraction was neutralized with satd. NaHCO 3 solution and extracted with ethyl acetate dried over MgSO 4 , filtered and concentrated.
  • the compounds of Formula I, particularly Formula IA can be prepared through the preparation shown in the Reaction Scheme 3 below.
  • the compounds of Formula I can be prepared through the preparation of intermediates shown in the Reaction Scheme 4 below Scheme 4.
  • the compounds of Formula II can be prepared through the preparation shown in the Reaction Scheme 5 below.
  • the reaction mixture was degassed using Argon for 10 min and then Pd 2 (dba) 2 (196 mg, 0.214 mmol) and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (153 mg, 0.32 mmol) were added.
  • the reaction flask was placed into the preheated oil-bath at 100 °C.
  • the reaction mixture was further stirred at 100 °C for a period of 4 hours after which, it was filtered and partitioned between ethyl acetate and water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate.
  • the reaction mixture was further stirred at 100 °C for a period of 6 hours after which, it was filtered and partitioned between ethyl acetate and water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over MgSO 4 , filtered and concentrated. The crude product was purified by flash column chromatography using a 9: 1 v/v Hexane:Ethyl acetate as solvent to afford title compound (185 mg, 69% yield).
  • a microwave tube was charged with 6-chloro-N-(2-(isopropylsulfonyl)phenyl)-1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrirrndin-4-amine (40 mg, 0.0917 mmol), 2- isopropoxy-5-methyl-4-(l-methylpiperidin-4-yl)benzenamine (72.3 mg, 0.275 mmol) 4N HCl in Dioxane (0.069 mL, 0.276 mmol) and ethylene glycol (1.5 mL). The tube was sealed and the reaction mixture was stirred at 180 °C for 30 min in a microwave reactor.
  • the reaction mixture was purified by reverse-phase preparative HPLC.
  • the crude TFA salt of product was neutralized with a satd. aqueous solution OfNaHCO 3 and extracted with ethyl acetate.
  • the organic layer was dried over sodium sulfate, filtered and concentrated.
  • the residue was purified by flash chromatography using 30: 1 :0.3 methylene chloride -methanol-triethylamine as solvent to afford the title compound (20.0 mg, 0.037 mmol).
  • Murine pro-B cell line Ba/F3 the human t(2,5)-positive Karpas-299 and TEL-ALK transformed Ba/F3 are maintained in RPMI medium 1640 supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO). Ba/F3 cells are grown in the presence of 10% of WEHI media. Cell lines expressing luciferase alone or in combination with TEL-kinase fusion constructs are generated by retroviral transduction of cells with pMSCV-IRES puro/Luc vector.
  • Luciferase-expressing Ba/F3 cells Karpas-299, Tel_ALK transformed Ba/F3 stably expressing NPM-ALK and TEL-ALK, are plated in 384-well plates (5,000 cells per well) and incubated with serial dilutions of ALK inhibitors or DMSO for 48 hours. Luciferase expression is used as a measure of cell proliferation/ survival and was evaluated with the Bright-Glo Luciferase Assay System (Promega, Madison, WI). Fifty percent inhibition values (IC 50 ) are generated by using XLFit software.
  • mice with established lymphomas are administered vehicle solution or test compound (typically 10 mg/kg) for 3 days.
  • test compound typically 10 mg/kg
  • ALK tyrosine kinase activity may also be measured using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF-R kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000).
  • the antiproliferative action of the compounds of the invention can also be determined in the human KARPAS-299 lympoma cell line (described in WG Dirks et al. Int. J. Cancer 100, 49-56 (2002) using the same methodology described above).
  • a cell-based assay consists of using a ETV6-NTRK3 transformed Ba/F3 cell line. This cell line may be used to discover compounds that are differentially cytotoxic as compared to parental Ba/F3 cells grown in the presence of IL-3. Compounds that are selectively cytotoxic to Ba/F3 ETV6-NTRK3 are confirmed using a biochemical NTRK3 kinase assay. Cellular inhibition of NTRK3 is confirmed using phosphospecific antibodies.
  • kinase, fluorescein-labeled substrate, and ATP are allowed to react. Then EDTA (to stop the reaction) and terbium-labeled antibody (to detect phosphorylated product) are added.
  • the antibody associates with the phosphorylated fluorescein labelled substrate resulting in an increased TR- FRET value.
  • the TR-FRET value is a dimensionless number that is calculated as the ratio of the acceptor (fluorescein) signal to the donor (terbium) signal.
  • the amount of antibody that is bound to the tracer is directly proportional to the amount of phosphorylated substrate present, and in this manner, kinase activity can be detected and measured by an increase in the TR- FRET value
  • FP Fluorescence Polarization
  • Binding assays for the following compound show kinases that are inhibited Numbers in the table are Kd (disassociation constants) in nanomolar. Representative Binding Assay Data
  • CLKl (CDC like kinase 1), IGFRl (insulin like growth factor receptor kinase 1); InsR (insulin receptor kinase), PTK2 (also known at FAK or focal adhesion kinase), PTK2B (also known as FAK2 or focal adhesion kinase 2), and TTK (also known as Mps 1) are shown to be inhibited.
  • WO 2005016894 - Garcia-echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya, Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro; Steensma, Ruo; Chopiuk, Greg; Jiang, Jiqing; Wan, Yongqin; Ding, Qiang; Zhang, Qiong; Gray, Nathanael Schiander; Karanewsky, Donald. Preparation of 2,4- pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. PCT Int. Appl. (2005), 285 pp.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés de pyrimidine substitués par amino, des compositions pharmaceutiques contenant ces composés, et l'utilisation de ces composés ou compositions pour traiter des troubles hyperproliferatifs et/ou associés à l'angiogenèse, ces composés ou compositions se présentant sous forme d'un agent unique ou étant combinés à d'autres substances actives.
PCT/US2008/074472 2007-08-28 2008-08-27 Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse Ceased WO2009032694A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008296479A AU2008296479A1 (en) 2007-08-28 2008-08-27 Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96644907P 2007-08-28 2007-08-28
US60/966,449 2007-08-28

Publications (1)

Publication Number Publication Date
WO2009032694A1 true WO2009032694A1 (fr) 2009-03-12

Family

ID=40111042

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2008/074472 Ceased WO2009032694A1 (fr) 2007-08-28 2008-08-27 Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse
PCT/US2008/074490 Ceased WO2009032703A1 (fr) 2007-08-28 2008-08-27 Composés et compositions inhibiteurs de kinase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2008/074490 Ceased WO2009032703A1 (fr) 2007-08-28 2008-08-27 Composés et compositions inhibiteurs de kinase

Country Status (2)

Country Link
AU (1) AU2008296479A1 (fr)
WO (2) WO2009032694A1 (fr)

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126515A1 (fr) * 2008-04-07 2009-10-15 Irm Llc Composés et compositions comme inhibiteurs de la protéine kinase
WO2010128659A1 (fr) 2009-05-08 2010-11-11 アステラス製薬株式会社 Composé de carboxamide hétérocyclique diamino
WO2011013729A1 (fr) 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Dérivé d'imidazole condensé présentant une activité inhibitrice envers ttk
WO2011060295A1 (fr) * 2009-11-13 2011-05-19 Genosco Inhibiteurs de kinases
WO2010111406A3 (fr) * 2009-03-24 2011-07-07 Myriad Pharmaceuticals, Inc. Composés et leurs utilisations thérapeutiques
ES2365960A1 (es) * 2010-03-31 2011-10-14 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
US8039479B2 (en) 2006-12-08 2011-10-18 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2011146313A1 (fr) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Composés de pyrazolopyrimidine pour le traitement du cancer
WO2012123745A1 (fr) * 2011-03-14 2012-09-20 Cancer Research Technology Limited Dérivés pyrrolopyridineamino en tant qu'inhibiteurs de mps1
US8318702B2 (en) 2007-07-06 2012-11-27 Astellas Pharma Inc. Di(arylamino)aryl compounds
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8563568B2 (en) 2010-08-10 2013-10-22 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
US8685988B2 (en) 2012-08-06 2014-04-01 Acea Biosciences, Inc. EGFR modulators and uses thereof
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
WO2015061369A1 (fr) * 2013-10-21 2015-04-30 Genosco Composés de pyrimidine substitués et leur utilisation en tant qu'inhibiteurs de syk
CN104672214A (zh) * 2013-12-03 2015-06-03 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
WO2015164614A1 (fr) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
WO2015164604A1 (fr) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US9334286B2 (en) 2012-09-07 2016-05-10 Cancer Research Technology Limited Pharmacologically active compounds
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
WO2016073771A3 (fr) * 2014-11-06 2016-07-28 Ohio State Innovation Foundation Dérivés de pyrrolopyrimidine utilisés en tant qu'inhibiteurs de la kinase mps1/ttk
US9409907B2 (en) 2012-09-07 2016-08-09 Cancer Research Technology Limited Inhibitor compounds
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9540351B2 (en) 2013-09-18 2017-01-10 Axikin Pharmaceuticals, Inc. Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9555031B2 (en) 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9567326B2 (en) 2012-05-22 2017-02-14 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
WO2017035354A1 (fr) * 2015-08-26 2017-03-02 Blueprint Medicines Corporation Composés et compositions utiles pour traiter des troubles associés au gène ntrk
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9834571B2 (en) 2012-05-05 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9902721B2 (en) 2014-02-28 2018-02-27 Cancer Research Technology Limited N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
CN107801397A (zh) * 2015-02-13 2018-03-13 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
US9932325B2 (en) 2016-06-16 2018-04-03 Denali Therapeutics Inc. Compounds, compositions, and methods
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10023579B2 (en) 2015-12-16 2018-07-17 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
KR101896568B1 (ko) * 2017-03-23 2018-09-10 재단법인 대구경북첨단의료산업진흥재단 피롤로-피리딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10144730B2 (en) 2011-11-17 2018-12-04 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
AU2015385326B2 (en) * 2015-03-04 2019-04-18 Novartis Ag Chemical process for preparing pyrimidine derivatives and intermediates thereof
US10370379B2 (en) 2015-11-19 2019-08-06 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
US10383847B2 (en) 2012-03-23 2019-08-20 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10562918B2 (en) 2013-07-11 2020-02-18 ACEA Therapeutics, Inc. Heterocyclic compounds and uses thereof
US10596174B2 (en) 2012-01-13 2020-03-24 ACEA Therapeutics, Inc. Pyrrolopyrimidine compounds as inhibitors of protein kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
CN111484484A (zh) * 2020-04-13 2020-08-04 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN112125884A (zh) * 2010-12-17 2020-12-25 诺华股份有限公司 制备嘧啶-2,4-二胺二盐酸盐的方法
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN113557237A (zh) * 2019-01-18 2021-10-26 沃若诺伊公司 吡咯并吡啶衍生物及其预防或治疗蛋白激酶相关疾病的用途
US11207321B2 (en) 2017-06-20 2021-12-28 The Institute Of Cancer Research: Royal Cancer Hospital Methods and medical uses
US11208696B2 (en) 2015-04-17 2021-12-28 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11248003B2 (en) 2017-12-07 2022-02-15 Oncobix Co., Ltd. Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3837361A4 (fr) * 2018-08-17 2022-06-15 National Health Research Institutes Complexe ahr-ror-gamma t utilisable en tant que biomarqueur et cible thérapeutique pour les maladies auto-immunes et les maladies associées à l'il-17a
US11498922B2 (en) 2017-04-07 2022-11-15 ACEA Therapeutics, Inc. Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
CN115368366A (zh) * 2022-08-02 2022-11-22 江苏省中医药研究院 嘧啶并吡唑类化合物及其应用
AU2020385527B2 (en) * 2019-11-21 2023-04-13 Tyk Medicines, Inc. Compound used as EGFR kinase inhibitor and use thereof
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US12194048B2 (en) 2020-12-09 2025-01-14 Voronoi Co., Ltd. Use of pyrrolopyridine derivatives for preventing or treating inflammatory diseases
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007756A1 (fr) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Dérivé de pyridine ayant une activité d'inhibition de la ttk
US9353107B2 (en) 2012-07-03 2016-05-31 Aurigene Discovery Technologies Limited 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
CN102746308B (zh) * 2012-07-09 2014-12-31 四川大学 别嘌醇衍生物及其制备方法和用途
EP2917210B1 (fr) 2012-11-06 2019-02-27 Shanghai Fochon Pharmaceutical Co. Ltd Inhibiteurs de kinase alk
CN105873913B (zh) 2013-09-10 2019-12-03 得克萨斯系统大学评议会 靶向截短的腺瘤性结肠息肉(apc)蛋白的治疗法
GB201522532D0 (en) * 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
KR101937529B1 (ko) * 2016-07-26 2019-01-14 한국화학연구원 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018183112A1 (fr) * 2017-03-27 2018-10-04 Cardurion Pharmaceuticals, Llc Composé hétérocyclique
WO2019112344A1 (fr) * 2017-12-07 2019-06-13 주식회사 온코빅스 Nouveau dérivé de pyrimidine ayant pour effet d'inhiber la croissance de cellules cancéreuses, et composition pharmaceutique contenant celui-ci
MX2021003516A (es) 2018-09-25 2021-05-27 Cardurion Pharmaceuticals Llc Compuesto de aminopirimidina.
CN114829344B (zh) * 2019-12-16 2024-08-13 韩国化学研究院 新型嘧啶衍生物及包含其的药学组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016894A1 (fr) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire
US20070032515A1 (en) * 2003-07-23 2007-02-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US7241769B2 (en) * 2004-05-19 2007-07-10 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20070191344A1 (en) * 2003-09-15 2007-08-16 Axel Choidas Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960372B1 (fr) * 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Inhibiteurs de kinase et leurs utilisations
WO2008039359A2 (fr) * 2006-09-25 2008-04-03 Janssen Pharmaceutica N.V. Inhibiteurs de pyrimidine kinase bicyclique
ME00811B (fr) * 2006-12-08 2012-03-20 Novartis Ag Composés et compositions inhibant la protéine kinase
WO2008081928A1 (fr) * 2006-12-28 2008-07-10 Taisho Pharmaceutical Co., Ltd. Composé pyrazolopyridimidine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032515A1 (en) * 2003-07-23 2007-02-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2005016894A1 (fr) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire
US20070191344A1 (en) * 2003-09-15 2007-08-16 Axel Choidas Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
US7241769B2 (en) * 2004-05-19 2007-07-10 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors

Cited By (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957081B2 (en) 2006-12-08 2015-02-17 Irm Llc Compounds and compositions as protein kinase inhibitors
US8039479B2 (en) 2006-12-08 2011-10-18 Irm Llc Compounds and compositions as protein kinase inhibitors
US8399450B2 (en) 2006-12-08 2013-03-19 Irm Llc Compounds and compositions as protein kinase inhibitors
US8377921B2 (en) 2006-12-08 2013-02-19 Irm Llc Compounds and compositions as protein kinase inhibitors
US8372858B2 (en) 2006-12-08 2013-02-12 Irm Llc Compounds and compositions as protein kinase inhibitors
US8318702B2 (en) 2007-07-06 2012-11-27 Astellas Pharma Inc. Di(arylamino)aryl compounds
WO2009126515A1 (fr) * 2008-04-07 2009-10-15 Irm Llc Composés et compositions comme inhibiteurs de la protéine kinase
US8592432B2 (en) 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
EA018282B1 (ru) * 2008-04-07 2013-06-28 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
AU2009233964B2 (en) * 2008-04-07 2012-06-07 Irm Llc Compounds and compositions as protein kinase inhibitors
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US9296737B2 (en) 2008-06-27 2016-03-29 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US8609679B2 (en) 2008-06-27 2013-12-17 Celgene Avilomics Research, Inc. 2,4-diaminopyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US10010548B2 (en) 2008-06-27 2018-07-03 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US10828300B2 (en) 2008-06-27 2020-11-10 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8710222B2 (en) 2008-06-27 2014-04-29 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9409921B2 (en) 2008-06-27 2016-08-09 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines as kinase inhibitors
US10596172B2 (en) 2008-06-27 2020-03-24 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9212181B2 (en) 2008-06-27 2015-12-15 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9987276B2 (en) 2008-06-27 2018-06-05 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
WO2010111406A3 (fr) * 2009-03-24 2011-07-07 Myriad Pharmaceuticals, Inc. Composés et leurs utilisations thérapeutiques
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
EP3009428A1 (fr) 2009-05-08 2016-04-20 Astellas Pharma Inc. Composés de carboxamide hétérocycliques diamino
US8969336B2 (en) 2009-05-08 2015-03-03 Astellas Pharma Inc. Diamino heterocyclic carboxamide compound
US9487491B2 (en) 2009-05-08 2016-11-08 Astellas Pharma Inc. Diamino heterocyclic carboxamide compound
WO2010128659A1 (fr) 2009-05-08 2010-11-11 アステラス製薬株式会社 Composé de carboxamide hétérocyclique diamino
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
WO2011013729A1 (fr) 2009-07-30 2011-02-03 オンコセラピー・サイエンス株式会社 Dérivé d'imidazole condensé présentant une activité inhibitrice envers ttk
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
EA024729B1 (ru) * 2009-11-13 2016-10-31 Джиноско Киназные ингибиторы
CN102811619B (zh) * 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
CN102811619A (zh) * 2009-11-13 2012-12-05 金纳斯克公司 激酶抑制剂
AU2010319382A1 (en) * 2009-11-13 2012-04-19 Genosco Kinase inhibitors
WO2011060295A1 (fr) * 2009-11-13 2011-05-19 Genosco Inhibiteurs de kinases
ES2365960A1 (es) * 2010-03-31 2011-10-14 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
US9744172B2 (en) 2010-05-19 2017-08-29 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2011146313A1 (fr) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Composés de pyrazolopyrimidine pour le traitement du cancer
US9604936B2 (en) 2010-08-10 2017-03-28 Celgene Car Llc Besylate salt of a BTK inhibitor
US8563568B2 (en) 2010-08-10 2013-10-22 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
US10081606B2 (en) 2010-11-01 2018-09-25 Celgene Car Llc Heteroaryl compounds and uses thereof
US9867824B2 (en) 2010-11-01 2018-01-16 Celgene Car Llc Heterocyclic compounds and uses thereof
US9765038B2 (en) 2010-11-01 2017-09-19 Celgene Car Llc Heteroaryl compounds and uses thereof
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US11096942B2 (en) 2010-11-01 2021-08-24 Celgene Car Llc Heterocyclic compounds and uses thereof
US9375431B2 (en) 2010-11-01 2016-06-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors
US10434101B2 (en) 2010-11-01 2019-10-08 Celgene Car Llc Heterocyclic compounds and uses thereof
US9868723B2 (en) 2010-11-10 2018-01-16 Celgene Car Llc Mutant-selective EGFR inhibitors and uses thereof
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
US9409887B2 (en) 2010-11-10 2016-08-09 Celgene Avilomics Research, Inc. Mutant-selective EGFR inhibitors and uses thereof
CN112125884A (zh) * 2010-12-17 2020-12-25 诺华股份有限公司 制备嘧啶-2,4-二胺二盐酸盐的方法
AU2012228090B2 (en) * 2011-03-14 2017-03-30 Cancer Research Technology Limited Pyrrolopyridineamino derivatives as Mps1 inhibitors
WO2012123745A1 (fr) * 2011-03-14 2012-09-20 Cancer Research Technology Limited Dérivés pyrrolopyridineamino en tant qu'inhibiteurs de mps1
US9371319B2 (en) 2011-03-14 2016-06-21 Cancer Research Technology Limited Pyrrolopyridineamino derivatives as MPS1 inhibitors
CN103517903B (zh) * 2011-03-14 2017-03-01 癌症研究科技有限公司 作为mps1抑制剂的吡咯并吡啶氨基衍生物
CN103517903A (zh) * 2011-03-14 2014-01-15 癌症研究科技有限公司 作为mps1抑制剂的吡咯并吡啶氨基衍生物
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9795606B2 (en) 2011-10-03 2017-10-24 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US10179133B2 (en) 2011-10-03 2019-01-15 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US9273056B2 (en) 2011-10-03 2016-03-01 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US10144730B2 (en) 2011-11-17 2018-12-04 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US10981903B2 (en) 2011-11-17 2021-04-20 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US9920074B2 (en) 2012-01-13 2018-03-20 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US11612602B2 (en) 2012-01-13 2023-03-28 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9763949B2 (en) 2012-01-13 2017-09-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US10596174B2 (en) 2012-01-13 2020-03-24 ACEA Therapeutics, Inc. Pyrrolopyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US10799504B2 (en) 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
US9539255B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US10570099B2 (en) 2012-03-15 2020-02-25 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US10004741B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US11292772B2 (en) 2012-03-15 2022-04-05 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US10946016B2 (en) 2012-03-15 2021-03-16 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9540335B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US10005738B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9346792B2 (en) 2012-03-16 2016-05-24 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9365556B2 (en) 2012-03-16 2016-06-14 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9382237B2 (en) 2012-03-16 2016-07-05 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US10383847B2 (en) 2012-03-23 2019-08-20 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US9834571B2 (en) 2012-05-05 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9567326B2 (en) 2012-05-22 2017-02-14 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US11007197B2 (en) 2012-08-06 2021-05-18 ACEA Therapeutics, Inc. EGFR modulators and uses thereof
US10449196B2 (en) 2012-08-06 2019-10-22 ACEA Therapeutics, Inc. EGFR modulators and uses thereof
US8685988B2 (en) 2012-08-06 2014-04-01 Acea Biosciences, Inc. EGFR modulators and uses thereof
US9890157B2 (en) 2012-09-07 2018-02-13 Cancer Research Technology Limited Inhibitor compounds
US9895364B2 (en) 2012-09-07 2018-02-20 Cancer Research Technology Limited Pharmacologically active compounds
US10479788B2 (en) 2012-09-07 2019-11-19 Cancer Research Technology Limited Compounds that inhibit MPS1 kinase
US9834552B2 (en) 2012-09-07 2017-12-05 Cancer Research Technology Limited Inhibitor compounds
US9409907B2 (en) 2012-09-07 2016-08-09 Cancer Research Technology Limited Inhibitor compounds
US10188642B2 (en) 2012-09-07 2019-01-29 Cancer Research Technology Limited Pharmacologically active compounds
US11897877B2 (en) 2012-09-07 2024-02-13 Cancer Research Technology Limited Inhibitor compounds
US9334286B2 (en) 2012-09-07 2016-05-10 Cancer Research Technology Limited Pharmacologically active compounds
US11046688B2 (en) 2012-09-07 2021-06-29 Cancer Research Technology Limited Inhibitor compounds
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
US10787436B2 (en) 2012-10-18 2020-09-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9771330B2 (en) 2012-11-27 2017-09-26 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
US9549927B2 (en) 2012-12-21 2017-01-24 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9796700B2 (en) 2013-02-08 2017-10-24 Celgene Car Llc ERK inhibitors and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9504686B2 (en) 2013-02-08 2016-11-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9980964B2 (en) 2013-02-08 2018-05-29 Celgene Car Llc ERK inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US10562918B2 (en) 2013-07-11 2020-02-18 ACEA Therapeutics, Inc. Heterocyclic compounds and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9540351B2 (en) 2013-09-18 2017-01-10 Axikin Pharmaceuticals, Inc. Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CN105940000B (zh) * 2013-10-21 2019-12-24 盖诺斯克公司 取代的嘧啶化合物及其作为syk抑制剂的用途
WO2015061369A1 (fr) * 2013-10-21 2015-04-30 Genosco Composés de pyrimidine substitués et leur utilisation en tant qu'inhibiteurs de syk
EA030962B1 (ru) * 2013-10-21 2018-10-31 Джиноско Замещенные пиримидиновые соединения и их применение в качестве syk ингибиторов
US9212178B2 (en) 2013-10-21 2015-12-15 Genosco Substituted pyrimidine compounds and their use as SYK inhibitors
CN105940000A (zh) * 2013-10-21 2016-09-14 盖诺斯克公司 取代的嘧啶化合物及其作为syk抑制剂的用途
CN104672214A (zh) * 2013-12-03 2015-06-03 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015081813A1 (fr) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 Composé présentant une activité d'inhibition d'alk et sa préparation et son utilisation
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105612151B (zh) * 2013-12-03 2017-08-15 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9902721B2 (en) 2014-02-28 2018-02-27 Cancer Research Technology Limited N2-phenyl-pyrido[3,4-d]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors
US10399974B2 (en) 2014-02-28 2019-09-03 Cancer Research Technology Limited N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors
US10004755B2 (en) 2014-04-11 2018-06-26 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
US9555030B2 (en) 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity
US9649309B2 (en) 2014-04-11 2017-05-16 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity
US9555031B2 (en) 2014-04-11 2017-01-31 The University Of North Carolina At Chapel Hill Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds
WO2015164604A1 (fr) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
WO2015164614A1 (fr) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10202364B2 (en) 2014-08-13 2019-02-12 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10611765B2 (en) 2014-11-06 2020-04-07 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors
WO2016073771A3 (fr) * 2014-11-06 2016-07-28 Ohio State Innovation Foundation Dérivés de pyrrolopyrimidine utilisés en tant qu'inhibiteurs de la kinase mps1/ttk
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US9730914B2 (en) 2014-12-23 2017-08-15 Axikin Pharmaceuticals 3,5-diaminopyrazole kinase inhibitors
US12168663B2 (en) 2014-12-23 2024-12-17 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3778605A3 (fr) * 2015-02-13 2021-03-10 Dana Farber Cancer Institute, Inc. Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
EP3778604A1 (fr) * 2015-02-13 2021-02-17 Dana Farber Cancer Institute, Inc. Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
CN107801397A (zh) * 2015-02-13 2018-03-13 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
AU2015385326B2 (en) * 2015-03-04 2019-04-18 Novartis Ag Chemical process for preparing pyrimidine derivatives and intermediates thereof
AU2019202552B2 (en) * 2015-03-04 2020-10-29 Novartis Ag Chemical process for preparing pyrimidine derivatives and intermediates thereof
US12098154B2 (en) 2015-03-27 2024-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11325910B2 (en) 2015-03-27 2022-05-10 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US12054784B2 (en) 2015-04-17 2024-08-06 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
US11208696B2 (en) 2015-04-17 2021-12-28 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10017512B2 (en) 2015-08-26 2018-07-10 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
CN108137607A (zh) * 2015-08-26 2018-06-08 蓝图药品公司 适用于治疗与ntrk相关的病症的化合物和组合物
US11046697B2 (en) 2015-08-26 2021-06-29 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
WO2017035354A1 (fr) * 2015-08-26 2017-03-02 Blueprint Medicines Corporation Composés et compositions utiles pour traiter des troubles associés au gène ntrk
JP2018528200A (ja) * 2015-08-26 2018-09-27 ブループリント メディシンズ コーポレイション Ｎｔｒｋ関連障害の治療に有用な化合物および組成物
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
US11059827B2 (en) 2015-11-19 2021-07-13 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
US10370379B2 (en) 2015-11-19 2019-08-06 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US10023579B2 (en) 2015-12-16 2018-07-17 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
US10294235B2 (en) 2015-12-16 2019-05-21 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
US11840529B2 (en) 2016-03-11 2023-12-12 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US11591316B2 (en) 2016-06-16 2023-02-28 Denali Therapeutics Inc. Compounds, compositions, and methods
US10590114B2 (en) 2016-06-16 2020-03-17 Denali Therapautics Inc. Compounds, compositions, and methods
US9932325B2 (en) 2016-06-16 2018-04-03 Denali Therapeutics Inc. Compounds, compositions, and methods
US11111235B2 (en) 2016-06-16 2021-09-07 Denali Therapeutics Inc. Compounds, compositions, and methods
US11834439B2 (en) 2016-06-16 2023-12-05 Denali Therapeutics Inc. Compounds, compositions, and methods
KR101896568B1 (ko) * 2017-03-23 2018-09-10 재단법인 대구경북첨단의료산업진흥재단 피롤로-피리딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
US11117892B2 (en) 2017-03-23 2021-09-14 Daegu-Gyeongbuk Medical Innovation Foundation Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
US11498922B2 (en) 2017-04-07 2022-11-15 ACEA Therapeutics, Inc. Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
US11207321B2 (en) 2017-06-20 2021-12-28 The Institute Of Cancer Research: Royal Cancer Hospital Methods and medical uses
US11248003B2 (en) 2017-12-07 2022-02-15 Oncobix Co., Ltd. Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
EP3837361A4 (fr) * 2018-08-17 2022-06-15 National Health Research Institutes Complexe ahr-ror-gamma t utilisable en tant que biomarqueur et cible thérapeutique pour les maladies auto-immunes et les maladies associées à l'il-17a
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN113557237A (zh) * 2019-01-18 2021-10-26 沃若诺伊公司 吡咯并吡啶衍生物及其预防或治疗蛋白激酶相关疾病的用途
EP3915985A4 (fr) * 2019-01-18 2022-09-28 Voronoi Co., Ltd. Dérivé de pyrrolopyridine et son utilisation dans la prévention et le traitement d'une maladie liée à la protéine kinase
JP2022518723A (ja) * 2019-01-18 2022-03-16 ボロノイ・カンパニー・リミテッド ピロロピリジン誘導体およびタンパク質キナーゼ関連疾患の予防または治療での使用のためのその用途
US12240844B2 (en) 2019-01-18 2025-03-04 Voronoi, Inc. Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
JP7564983B2 (ja) 2019-01-18 2024-10-10 ボロノイ インコーポレイテッド ピロロピリジン誘導体およびタンパク質キナーゼ関連疾患の予防または治療での使用のためのその用途
AU2020385527B2 (en) * 2019-11-21 2023-04-13 Tyk Medicines, Inc. Compound used as EGFR kinase inhibitor and use thereof
CN111484484A (zh) * 2020-04-13 2020-08-04 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
US12194048B2 (en) 2020-12-09 2025-01-14 Voronoi Co., Ltd. Use of pyrrolopyridine derivatives for preventing or treating inflammatory diseases
CN115368366A (zh) * 2022-08-02 2022-11-22 江苏省中医药研究院 嘧啶并吡唑类化合物及其应用

Also Published As

Publication number Publication date
WO2009032703A1 (fr) 2009-03-12
AU2008296479A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2009032694A1 (fr) Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse
AU2021245150C1 (en) KRAS G12C inhibitors and methods of using the same
KR102558066B1 (ko) Tam 억제제로서 피롤로트리아진 화합물
US10421761B2 (en) Compounds for kinase modulation, and indications therefor
EP3399968B1 (fr) Inhibiteurs sélectifs de mutants cliniquement importants de la tyrosine kinase de l'egfr
US8829185B2 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US20100063038A1 (en) Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis
JP2020531501A (ja) Ｂｃｌ−２阻害剤
EP4092029A1 (fr) Dérivé de 7-amino-3,4-dihydropyrimidopyrimidin-2-one ayant une activité inhibitrice vis-à-vis des protéines kinases et composition pharmaceutique thérapeutique comprenant celui-ci
SG192686A1 (en) Compounds and methods for kinase modulation, and indications therefor
WO2022148317A1 (fr) Composé de 2-aminopyrimidine et composition pharmaceutique le comprenant et application associée
CA3037097C (fr) Derives de 3- (4,5-substitue pyrimidinamine) phenyle deuteres et leurs applications
CN111356687A (zh) 含嘧啶的三取代咪唑类化合物及其应用
US20250129047A1 (en) Isoquinoline derivatives as mutant egfr modulators and uses thereof
WO2024153077A1 (fr) Inhibiteur de hpk1, son procédé de préparation et son utilisation
CN116063283A (zh) 3-氨基吲唑类化合物及其应用
WO2020192302A1 (fr) Composé d'imidazole tri-substitué contenant de la pyrimidine et utilisation associée
TW201245175A (en) New 5-alkynyl-pyridines
HK1178153B (en) Triazolopyridines
HK1178153A1 (zh) 三唑并吡啶
HK1180333A1 (zh) 取代三唑并吡啶

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08798804

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008296479

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008296479

Country of ref document: AU

Date of ref document: 20080827

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 08798804

Country of ref document: EP

Kind code of ref document: A1